Contact

Ivoran Home About Services Evidence Review Risks & Safety Guide for Families Contact Evidence, limits & safety Ibogaine Treatment for Alzheimer's A careful look at a question shaped by urgent need, early science, and serious uncertainty. Evidence before hype The essential point Interest is not evidence of benefit. Ibogaine treatment for alzheimer's is not an established treatment option. There is no credible clinical evidence that ibogaine improves Alzheimer’s outcomes in people, and it is not approved or recommended for Alzheimer’s disease. Alzheimer’s disease is a neurodegenerative disease marked by progressive cognitive decline, memory loss, and changes in brain cells. The unmet need is real, but biological plausibility does not establish safety or effectiveness. For a wider discussion of dementia-focused claims, the overview of ibogaine and dementia may help separate questions from conclusions. A useful baseline is the National Institute on Aging’s Alzheimer’s guidance , which describes established care information without presenting ibogaine as a treatment. A grounded starting point Ibogaine is best known in addiction treatment discussions, particularly around drug dependence and withdrawal symptoms. That history does not demonstrate a role in Alzheimer’s disease. Older adults may have coexisting illness, medication use, or cardiac vulnerability. Those facts make patient safety and medical supervision central—not secondary—to any conversation. Origin & tradition What ibogaine is—and what its history does not prove Ibogaine is an indole alkaloid derived from the root bark of the Tabernanthe iboga shrub, native to West Central Africa. For centuries, indigenous cultures, particularly the Bwiti spiritual tradition in Gabon, have used iboga in ceremonial practices for healing, spiritual exploration, and initiation rites. Traditional use includes small doses for general well-being and fatigue relief, while larger doses can induce intense psychedelic exper

Published channels